NCT00543491终止3 期
MK0767 and Sulfonylurea Combination Study (0767-027)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 129
研究概览
简要总结
This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 78 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes with inadequate glycemic control
- •On Sulfonylurea monotherapy
- •Male or non-pregnant Females
- •Age 21 to 78 years, inclusive
- •On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6
排除标准
- •History of Type 1 diabetes
- •Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents
- •Patients with history of or intolerance of PPAR-y agonists
研究者
相似试验
终止
3 期
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)Diabetes Mellitus, Type 2NCT00543816Merck Sharp & Dohme LLC100
终止
2 期
MK0767 in Type 2 Diabetes (0767-012)Type 2 Diabetes MellitusNCT00543556Merck Sharp & Dohme LLC514
终止
3 期
Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)Diabetes Mellitus, Type 2NCT00543751Merck Sharp & Dohme LLC610
终止
3 期
Study A - MK0767 Monotherapy StudyDiabetes Mellitus, Type 2NCT00543517Merck Sharp & Dohme LLC99
终止
3 期
MK0767 and Metformin Combination Study (0767-028)Diabetes MellitusNCT00543738Merck Sharp & Dohme LLC114